Ikena Oncology (NASDAQ:IKNA) Given "Outperform" Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Ikena Oncology (NASDAQ:IKNA – Free Report) in a research note released on Tuesday morning, Benzinga reports. Wedbush currently has a $8.00 price objective on the stock. Wedbush also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 […]

Related Keywords

United States , , Jacobs Levy Equity Management Inc , Acadian Asset Management , Marquette Asset Management , Ikena Oncology Inc , Ikena Oncology , Free Report , Get Free Report , Levy Equity Management , Asset Management , Vestal Point Capital , Ikena Oncology Daily ,